<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="article-commentary" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Mol Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Mol Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">Front. Mol. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Molecular Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1662-5099</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28223919</article-id>
<article-id pub-id-type="pmc">5293769</article-id>
<article-id pub-id-type="doi">10.3389/fnmol.2017.00029</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>General Commentary</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Commentary: Depletion of the Fragile X Mental Retardation Protein in Embryonic Stem Cells Alters the Kinetics of Neurogenesis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Westmark</surname>
<given-names>Cara J.</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/83193/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff>
<institution>Department of Neurology, University of Wisconsin</institution>
<country>Madison, WI, USA</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Regina Dahlhaus, Friedrich Alexander University Erlangen-Nürnberg, Germany</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Claes Wahlestedt, University of Miami School of Medicine, USA; Corrado Romano, IRCCS Associazione Oasi Maria Santissima, Italy</p>
</fn>
<corresp id="fn001">*Correspondence: Cara J. Westmark <email xlink:type="simple">westmark@wisc.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>10</volume>
<elocation-id>29</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>12</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>1</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 Westmark.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Westmark</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<related-article ext-link-type="pubmed" id="d35e96" journal-id="Stem Cells" journal-id-type="nlm-ta" page="374" related-article-type="commentary-article" vol="35" xlink:href="27664080">A commentary on <article-title>Depletion of the Fragile X Mental Retardation Protein in Embryonic Stem Cells Alters the Kinetics of Neurogenesis</article-title> by Khalfallah, O., Jariat, M., Davidovic, L., Nottet, N., Cestèle, S., Mantegazza, M., et al. (2017). Stem Cells 35, 374–385. doi: <object-id>10.1002/stem.2505</object-id></related-article>
<kwd-group>
<kwd>APP</kwd>
<kwd>FMRP</kwd>
<kwd>fragile X syndrome</kwd>
<kwd>secretases</kwd>
<kwd>neurogenesis</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">U.S. Department of Defense<named-content content-type="fundref-id">10.13039/100000005</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn002">FRAXA Research Foundation<named-content content-type="fundref-id">10.13039/100000297</named-content></funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="43"></ref-count>
<page-count count="5"></page-count>
<word-count count="3419"></word-count>
</counts>
</article-meta>
</front>
<body>
<p>Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by cognitive impairment, attention deficit, hyperactivity, anxiety, unstable mood, autistic behaviors, language delay, and seizures (Hagerman et al., <xref ref-type="bibr" rid="B14">2010</xref>). This X-linked chromosome disorder is the most common known cause of autism with 30% of boys meeting full autism criteria (Harris et al., <xref ref-type="bibr" rid="B16">2008</xref>). In the majority of cases, FXS is caused by a trinucleotide repeat expansion (CGG) in the <italic>FMR1</italic> gene, which causes loss of expression of fragile X mental retardation protein (FMRP) (Santoro et al., <xref ref-type="bibr" rid="B32">2011</xref>). FMRP is an RNA binding protein that plays a critical role in synaptic protein synthesis. There are medications for managing symptoms of FXS, but there are no disease specific therapies and no cure.</p>
<p>The main challenges confronting the FXS field include early diagnosis, validating outcome measures for clinical trials, and identifying viable treatment targets. In terms of early diagnosis, population wide screening is feasible. Recent advances in <italic>FMR1</italic> allele analysis allow rapid and inexpensive assessment of CGG repeat size, the number of AGG interruptions, and methylation status from blood or saliva samples (Hayward et al., <xref ref-type="bibr" rid="B18">2016</xref>). However, a FXS genetic test is not included in the newborn screening (NBS) panel in the United States due to ethical debates regarding screening for genetic disorders where no therapeutic intervention exists and contemporaneous identification of premutation carriers. Proponents of FXS NBS argue that screening is needed for early detection and intervention (Tassone, <xref ref-type="bibr" rid="B34">2014</xref>). Numerous disease mechanism-based drugs are in clinical trials for FXS and early intervention may be required for better therapeutic efficacy. Preliminary results indicate that babies with <italic>FMR1</italic> premutations exhibit an altered developmental trajectory on measures of nonverbal communication and hyperresponsivity to sensory experiences (Wheeler et al., <xref ref-type="bibr" rid="B43">2016</xref>). Thus, early diagnosis could benefit both full and premutation carriers.</p>
<p>With regard to the urgent need to validate outcome measures for FXS clinical trials, recent trials failed on primary endpoints (Berry-Kravis et al., <xref ref-type="bibr" rid="B5">2013</xref>, <xref ref-type="bibr" rid="B4">2016</xref>). Soluble amyloid precursor protein alpha (sAPPα) is elevated in plasma of autistic children and can be detected in human umbilical cord blood supporting feasibility of this APP metabolite as an early diagnostic autism biomarker (Sokol et al., <xref ref-type="bibr" rid="B33">2006</xref>; Bailey et al., <xref ref-type="bibr" rid="B1">2008</xref>). APP metabolites are also altered in FXS (Westmark et al., <xref ref-type="bibr" rid="B41">2016</xref>), and a recent trial with acamprosate indicates that sAPPα is responsive to drug treatment (Erickson et al., <xref ref-type="bibr" rid="B11">2014</xref>).</p>
<p>Concerning identification of viable treatment targets, excessive signaling through metabotropic glutamate receptor 5 (mGluR<sub>5</sub>) leads to increased translation of numerous synaptic proteins and altered plasticity in FXS (Bear et al., <xref ref-type="bibr" rid="B2">2004</xref>). Many of these proteins are under investigation as potential FXS drug targets. Of relevance herein, two overexpressed proteins are APP and amyloid-beta (Westmark and Malter, <xref ref-type="bibr" rid="B40">2007</xref>), which have been well-studied in Alzheimer's disease (AD). Accumulating evidence suggests that dysregulated levels of APP metabolites contribute to FXS pathology (Figure <xref ref-type="fig" rid="F1">1</xref>), supporting the hypothesis that pharmaceuticals under study for modulation of APP and amyloid-beta in AD may be viable therapeutic strategies for FXS (Westmark et al., <xref ref-type="bibr" rid="B39">2013</xref>; Pasciuto et al., <xref ref-type="bibr" rid="B28">2015</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p><bold>The APP Theory of FXS</bold>. FXS is a debilitating genetic disorder with no cure and few therapeutic options. Excessive signaling through mGluR<sub>5</sub> leads to the increased translation of numerous synaptic proteins and exaggerated long-term depression (LTD) in <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice (Huber et al., <xref ref-type="bibr" rid="B19">2002</xref>; Bear et al., <xref ref-type="bibr" rid="B2">2004</xref>). Two of the overexpressed proteins are APP and its metabolite amyloid-beta (Westmark and Malter, <xref ref-type="bibr" rid="B40">2007</xref>), which have been well-studied in Alzheimer's disease (AD). Accumulating evidence suggests that dysregulated levels of APP and its catabolites contribute to FXS pathology. Multiple recent FXS clinical trials have failed on their primary endpoints indicating that there is a compelling need for validated biomarkers and outcome measures in the field. We hypothesize that APP and its metabolites may be viable blood-based biomarkers that are responsive to drug treatment in FXS, and that pharmaceuticals under study for the modulation of APP and amyloid-beta in AD may be viable therapeutic candidates for FXS. In mice, FMRP binds to a guanine-rich region in the coding region of <italic>App</italic> mRNA and regulates protein translation through mGluR<sub>5</sub> signaling (Westmark and Malter, <xref ref-type="bibr" rid="B40">2007</xref>). APP and amyloid-beta levels are elevated in <italic>Fmr1</italic><sup><italic>KO</italic></sup> brain (Westmark and Malter, <xref ref-type="bibr" rid="B40">2007</xref>; Liao et al., <xref ref-type="bibr" rid="B22">2008</xref>; Pasciuto et al., <xref ref-type="bibr" rid="B28">2015</xref>); and behavior, dendritic spine, electrophysiology, and seizure phenotypes are rescued after genetic or pharmaceutical modulation of APP levels in <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice (Westmark et al., <xref ref-type="bibr" rid="B42">2011</xref>; Pasciuto et al., <xref ref-type="bibr" rid="B28">2015</xref>). These data prompted studies in human samples to determine if APP metabolites may be viable biomarkers for drug efficacy in FXS. In humans, there are altered levels of APP metabolites in FXS blood plasma, lymphoblastoid cells, and brain (Westmark et al., <xref ref-type="bibr" rid="B42">2011</xref>; Pasciuto et al., <xref ref-type="bibr" rid="B28">2015</xref>; Ray et al., <xref ref-type="bibr" rid="B30">2016</xref>); and sAPPα levels are responsive to drug treatment in FXS children (Erickson et al., <xref ref-type="bibr" rid="B11">2014</xref>). FXS is a family of disorders where older premutation carriers can develop fragile X tremor-ataxia syndrome (FXTAS). Elderly FXTAS subjects have elevated <italic>APP</italic> mRNA in blood and APP and amyloid plaques in brain; aged FXTAS knockin mice exhibit elevated brain APP (Tassone et al., <xref ref-type="bibr" rid="B35">2012</xref>; Mateu-Huertas et al., <xref ref-type="bibr" rid="B25">2014</xref>; Renoux et al., <xref ref-type="bibr" rid="B31">2014</xref>). Findings from the mouse and human studies prompted cell culture experiments. In human neuroblastoma cells, there is dual regulation of APP mRNA translation by the RNA binding proteins hnRNP C and FMRP, which compete for binding the guanine-rich regulatory element in the coding region of the message (Lee et al., <xref ref-type="bibr" rid="B21">2010</xref>). There is increased expression of APP in <italic>Fmr1</italic><sup><italic>KO</italic></sup> mouse cortical neurons and mESC; and genetic, lentiviral or pharmaceutical modulation of APP rescues spine morphology and accelerated neurogenesis (Westmark and Malter, <xref ref-type="bibr" rid="B40">2007</xref>; Westmark et al., <xref ref-type="bibr" rid="B42">2011</xref>; Pasciuto et al., <xref ref-type="bibr" rid="B28">2015</xref>; Khalfallah et al., <xref ref-type="bibr" rid="B20">2017</xref>). FMRP depletion in mESC leads to increased expression of APP and <italic>Ascl1</italic>, which leads to accelerated neuronal differentiation (Khalfallah et al., <xref ref-type="bibr" rid="B20">2017</xref>). Ascl1 is a transcription factor, and of interest, amyloid-beta is a putative transcription factor for <italic>APP</italic> and <italic>BACE1</italic> (Maloney and Lahiri, <xref ref-type="bibr" rid="B24">2011</xref>) and upregulates Ascl1 expression (Uchida et al., <xref ref-type="bibr" rid="B36">2007</xref>). Thus, enhanced transcriptional and translational events mediated by Ascl1, APP and amyloid-beta in the absence of FMRP could drive accelerated neurogenesis in FXS. The FXS mESC model developed by the Bardoni laboratory could be utilized to study cell signaling events at the earliest stage of FXS pathology, including APP synthesis and processing, and be developed into a high throughput assay for drug testing including secretase modulators. Bench-to-bedside plans would need to include validation of identified targets and drugs in future animal and human studies. Overall, this novel mESC model offers a timely tool to study the early events of FXS pathogenesis including the expression and processing of APP.</p>
</caption>
<graphic xlink:href="fnmol-10-00029-g0001"></graphic>
</fig>
<p>In their <italic>Stem Cell</italic>s article, Khalfallah and colleagues report the development of a mouse embryonic stem cell (mESC)-based FXS disease model. Specifically, they generated an isogenic stable cell line by targeted knockdown of the <italic>Fmr1</italic> gene with a short hairpin (sh)RNA, and used this model to demonstrate that decreased expression of FMRP triggers accelerated differentiation of neurons and elevated expression of the transcription factor Ascl1/Mash1 and the membrane glycoprotein APP (Khalfallah et al., <xref ref-type="bibr" rid="B20">2017</xref>). <italic>Fmr1</italic> mRNA and protein levels were specifically and significantly reduced in <italic>shFmr1</italic> mESC compared to control cells while expression of FMRP homologs was unaffected. <italic>Fmr1</italic> knockdown did not alter mESC morphology or proliferation; however, there was premature generation of neural progenitors as evidenced by a rosette-like morphology at 4 days <italic>in vitro</italic> and altered expression of neuro-specific markers. The authors confirmed that neurogenesis was accelerated <italic>in vivo</italic> in <italic>Fmr1</italic><sup><italic>KO</italic></sup> mouse embryonic brain. They further showed that accelerated neurogenesis in the <italic>shFmr1</italic> mESC model was rescued by genetic introduction of the human <italic>FMR1</italic> gene or pharmacological treatment with BACE-1 inhibitor LY2811376.</p>
<p>Neurogenesis is the process through which neurons are generated from neural stem and progenitor cells. Both FMRP a<italic>n</italic>d APP have evolutionarily conserved roles in regulating embryonic and adult neurogenesis (Hayashi et al., <xref ref-type="bibr" rid="B17">1994</xref>; Ohsawa et al., <xref ref-type="bibr" rid="B27">1999</xref>; Caille et al., <xref ref-type="bibr" rid="B6">2004</xref>; Callan et al., <xref ref-type="bibr" rid="B8">2010</xref>; Luo et al., <xref ref-type="bibr" rid="B23">2010</xref>; Demars et al., <xref ref-type="bibr" rid="B10">2011</xref>; Nicolas and Hassan, <xref ref-type="bibr" rid="B26">2014</xref>; Wang et al., <xref ref-type="bibr" rid="B37">2014</xref>, <xref ref-type="bibr" rid="B38">2016</xref>; Faulkner et al., <xref ref-type="bibr" rid="B13">2015</xref>; Halevy et al., <xref ref-type="bibr" rid="B15">2015</xref>). FMRP regulates the translation of both Ascl1 (Fahling et al., <xref ref-type="bibr" rid="B12">2009</xref>) and APP (Westmark and Malter, <xref ref-type="bibr" rid="B40">2007</xref>; Lee et al., <xref ref-type="bibr" rid="B21">2010</xref>). Ascl1 is involved in the transcriptional regulation of genes associated with all major steps of neurogenesis (Castro et al., <xref ref-type="bibr" rid="B9">2011</xref>). APP expression, trafficking, and processing are dynamically regulated during neuronal differentiation (Bergstrom et al., <xref ref-type="bibr" rid="B3">2016</xref>; Ramaker et al., <xref ref-type="bibr" rid="B29">2016</xref>). The APP metabolite amyloid-beta upregulates expression of Ascl1 (Uchida et al., <xref ref-type="bibr" rid="B36">2007</xref>) and drives the differentiation of progenitor cells toward a neuronal lineage (Calafiore et al., <xref ref-type="bibr" rid="B7">2006</xref>). Thus, defective crosstalk among Asc1 and APP metabolites in the absence of FMRP likely contributes to accelerated neurogenesis in FXS. Early interventions targeted at normalizing this signaling pathway could promote normal brain development.</p>
<p>The <italic>shFmr1</italic> mESC model developed by the Bardoni laboratory overcomes the inherent ethical and scientific problems associated with human <italic>FMR1</italic> embryonic stem cells (hESC), most of which carry the methylated and silenced full mutation and/or are mosaic in CGG-repeat length and exhibit residual FMRP expression. In essence, this elegant work addresses the three main challenges of the FXS field by: (1) developing a <italic>Fmr1</italic> knockdown stem cell model that allows study of the earliest events of neurogenesis to support NBS and early intervention; (2) identifying a role for APP in the kinetics of neurogenesis, which supports the development of APP metabolites as potential FXS biomarkers; and (3) demonstrating rescue of <italic>shFmr1</italic> mESC morphology with a BACE-1 inhibitor thus promoting study of APP and secretases as therapeutic targets for FXS.</p>
<p>Khalfallah and colleagues contribute a vital piece to the FXS puzzle in describing development of a mESC model that allows study of early molecular events underlying disease development and provides a new platform for preclinical drug testing. Substantial data is provided validating the morphological and molecular characteristics of the <italic>shFmr1</italic> mESC as well as demonstrating rescue of phenotypes by re-introduction of FMRP or by targeting APP processing via inhibition of BACE-1. Future experiments could examine expression of various APP metabolites on neurogenesis, compare BACE-1 and mGluR<sub>5</sub> inhibitors, confirm FXS signaling pathways in this early disease-stage model, and transfect plasmids carrying varying length CGG repeats in the human <italic>FMR1</italic> gene to mimic the repeat expansion aspect of the disorder.</p>
<sec id="s1">
<title>Author contributions</title>
<p>The author confirms being the sole contributor of this work and approved it for publication.</p>
<sec>
<title>Conflict of interest statement</title>
<p>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>CW was supported by FRAXA Research Foundation and the Department of Defense (W81XWH-16-1-0082).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>A. R.</given-names></name><name><surname>Giunta</surname><given-names>B. N.</given-names></name><name><surname>Obregon</surname><given-names>D.</given-names></name><name><surname>Nikolic</surname><given-names>W. V.</given-names></name><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Sanberg</surname><given-names>C. D.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Peripheral biomarkers in Autism: secreted amyloid precursor protein-alpha as a probable key player in early diagnosis</article-title>. <source/>Int. J. Clin. Exp. Med.
<volume>1</volume>, <fpage>338</fpage>–<lpage>344</lpage>. <pub-id pub-id-type="pmid">19079679</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bear</surname><given-names>M. F.</given-names></name><name><surname>Huber</surname><given-names>K. M.</given-names></name><name><surname>Warren</surname><given-names>S. T.</given-names></name></person-group> (<year>2004</year>). <article-title>The mGluR theory of fragile X mental retardation</article-title>. <source/>Trends Neurosci.
<volume>27</volume>, <fpage>370</fpage>–<lpage>377</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2004.04.009</pub-id><pub-id pub-id-type="pmid">15219735</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergstrom</surname><given-names>P.</given-names></name><name><surname>Agholme</surname><given-names>L.</given-names></name><name><surname>Nazir</surname><given-names>F. H.</given-names></name><name><surname>Satir</surname><given-names>T. M.</given-names></name><name><surname>Toombs</surname><given-names>J.</given-names></name><name><surname>Wellington</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation</article-title>. <source/>Sci. Rep.
<volume>6</volume>:<fpage>29200</fpage>. <pub-id pub-id-type="doi">10.1038/srep29200</pub-id><pub-id pub-id-type="pmid">27383650</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry-Kravis</surname><given-names>E.</given-names></name><name><surname>Des Portes</surname><given-names>V.</given-names></name><name><surname>Hagerman</surname><given-names>R.</given-names></name><name><surname>Jacquemont</surname><given-names>S.</given-names></name><name><surname>Charles</surname><given-names>P.</given-names></name><name><surname>Visootsak</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials</article-title>. <source/>Sci. Transl. Med.
<volume>8</volume>:<fpage>321ra5</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aab4109</pub-id><pub-id pub-id-type="pmid">26764156</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry-Kravis</surname><given-names>E.</given-names></name><name><surname>Hessl</surname><given-names>D.</given-names></name><name><surname>Abbeduto</surname><given-names>L.</given-names></name><name><surname>Reiss</surname><given-names>A. L.</given-names></name><name><surname>Beckel-Mitchener</surname><given-names>A.</given-names></name><name><surname>Urv</surname><given-names>T. K.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Outcome measures for clinical trials in fragile X syndrome</article-title>. <source/>J. Dev. Behav. Pediatr.
<volume>34</volume>, <fpage>508</fpage>–<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1097/DBP.0b013e31829d1f20</pub-id><pub-id pub-id-type="pmid">24042082</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caille</surname><given-names>I.</given-names></name><name><surname>Allinquant</surname><given-names>B.</given-names></name><name><surname>Dupont</surname><given-names>E.</given-names></name><name><surname>Bouillot</surname><given-names>C.</given-names></name><name><surname>Langer</surname><given-names>A.</given-names></name><name><surname>Muller</surname><given-names>U.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone</article-title>. <source/>Development
<volume>131</volume>, <fpage>2173</fpage>–<lpage>2181</lpage>. <pub-id pub-id-type="doi">10.1242/dev.01103</pub-id><pub-id pub-id-type="pmid">15073156</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calafiore</surname><given-names>M.</given-names></name><name><surname>Battaglia</surname><given-names>G.</given-names></name><name><surname>Zappala</surname><given-names>A.</given-names></name><name><surname>Trovato-Salinaro</surname><given-names>E.</given-names></name><name><surname>Caraci</surname><given-names>F.</given-names></name><name><surname>Caruso</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Progenitor cells from the adult mouse brain acquire a neuronal phenotype in response to beta-amyloid</article-title>. <source/>Neurobiol. Aging
<volume>27</volume>, <fpage>606</fpage>–<lpage>613</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2005.03.019</pub-id><pub-id pub-id-type="pmid">15964102</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callan</surname><given-names>M. A.</given-names></name><name><surname>Cabernard</surname><given-names>C.</given-names></name><name><surname>Heck</surname><given-names>J.</given-names></name><name><surname>Luois</surname><given-names>S.</given-names></name><name><surname>Doe</surname><given-names>C. Q.</given-names></name><name><surname>Zarnescu</surname><given-names>D. C.</given-names></name></person-group> (<year>2010</year>). <article-title>Fragile X protein controls neural stem cell proliferation in the Drosophila brain</article-title>. <source/>Hum. Mol. Genet.
<volume>19</volume>, <fpage>3068</fpage>–<lpage>3079</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddq213</pub-id><pub-id pub-id-type="pmid">20504994</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname><given-names>D. S.</given-names></name><name><surname>Martynoga</surname><given-names>B.</given-names></name><name><surname>Parras</surname><given-names>C.</given-names></name><name><surname>Ramesh</surname><given-names>V.</given-names></name><name><surname>Pacary</surname><given-names>E.</given-names></name><name><surname>Johnston</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>A novel function of the proneural factor Ascl1 in progenitor proliferation identified by genome-wide characterization of its targets</article-title>. <source/>Genes Dev.
<volume>25</volume>, <fpage>930</fpage>–<lpage>945</lpage>. <pub-id pub-id-type="doi">10.1101/gad.627811</pub-id><pub-id pub-id-type="pmid">21536733</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demars</surname><given-names>M. P.</given-names></name><name><surname>Bartholomew</surname><given-names>A.</given-names></name><name><surname>Strakova</surname><given-names>Z.</given-names></name><name><surname>Lazarov</surname><given-names>O.</given-names></name></person-group> (<year>2011</year>). <article-title>Soluble amyloid precursor protein: a novel proliferation factor of adult progenitor cells of ectodermal and mesodermal origin</article-title>. <source/>Stem Cell Res. Ther.
<volume>2</volume>:<fpage>36</fpage>. <pub-id pub-id-type="doi">10.1186/scrt77</pub-id><pub-id pub-id-type="pmid">21878106</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erickson</surname><given-names>C. A.</given-names></name><name><surname>Ray</surname><given-names>B.</given-names></name><name><surname>Maloney</surname><given-names>B.</given-names></name><name><surname>Wink</surname><given-names>L. K.</given-names></name><name><surname>Bowers</surname><given-names>K.</given-names></name><name><surname>Schaefer</surname><given-names>T. L.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Impact of acamprosate on plasma amyloid-beta precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker</article-title>. <source/>J. Psychiatr. Res.
<volume>59</volume>, <fpage>220</fpage>–<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpsychires.2014.07.011</pub-id><pub-id pub-id-type="pmid">25300441</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahling</surname><given-names>M.</given-names></name><name><surname>Mrowka</surname><given-names>R.</given-names></name><name><surname>Steege</surname><given-names>A.</given-names></name><name><surname>Kirschner</surname><given-names>K. M.</given-names></name><name><surname>Benko</surname><given-names>E.</given-names></name><name><surname>Forstera</surname><given-names>B.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Translational regulation of the human achaete-scute homologue-1 by fragile X mental retardation protein</article-title>. <source/>J. Biol. Chem.
<volume>284</volume>, <fpage>4255</fpage>–<lpage>4266</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M807354200</pub-id><pub-id pub-id-type="pmid">19097999</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faulkner</surname><given-names>R. L.</given-names></name><name><surname>Wishard</surname><given-names>T. J.</given-names></name><name><surname>Thompson</surname><given-names>C. K.</given-names></name><name><surname>Liu</surname><given-names>H. H.</given-names></name><name><surname>Cline</surname><given-names>H. T.</given-names></name></person-group> (<year>2015</year>). <article-title>FMRP regulates neurogenesis <italic>in vivo</italic> in <italic>Xenopus laevis</italic> tadpoles</article-title>. <source/>eNeuro
<volume>2</volume>:<fpage>e0055</fpage>. <pub-id pub-id-type="doi">10.1523/ENEURO.0055-14.2014</pub-id><pub-id pub-id-type="pmid">25844398</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagerman</surname><given-names>R.</given-names></name><name><surname>Hoem</surname><given-names>G.</given-names></name><name><surname>Hagerman</surname><given-names>P.</given-names></name></person-group> (<year>2010</year>). <article-title>Fragile X and autism: intertwined at the molecular level leading to targeted treatments</article-title>. <source/>Mol. Autism
<volume>1</volume>:<fpage>12</fpage>. <pub-id pub-id-type="doi">10.1186/2040-2392-1-12</pub-id><pub-id pub-id-type="pmid">20858229</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halevy</surname><given-names>T.</given-names></name><name><surname>Czech</surname><given-names>C.</given-names></name><name><surname>Benvenisty</surname><given-names>N.</given-names></name></person-group> (<year>2015</year>). <article-title>Molecular mechanisms regulating the defects in fragile X syndrome neurons derived from human pluripotent stem cells</article-title>. <source/>Stem Cell Reports
<volume>4</volume>, <fpage>37</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.stemcr.2014.10.015</pub-id><pub-id pub-id-type="pmid">25483109</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>S. W.</given-names></name><name><surname>Hessl</surname><given-names>D.</given-names></name><name><surname>Goodlin-Jones</surname><given-names>B.</given-names></name><name><surname>Ferranti</surname><given-names>J.</given-names></name><name><surname>Bacalman</surname><given-names>S.</given-names></name><name><surname>Barbato</surname><given-names>I.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Autism profiles of males with fragile X syndrome</article-title>. <source/>Am. J. Ment. Retard.
<volume>113</volume>, <fpage>427</fpage>–<lpage>438</lpage>
<pub-id pub-id-type="doi">10.1352/2008.113:427-438</pub-id><pub-id pub-id-type="pmid">19127654</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>Y.</given-names></name><name><surname>Kashiwagi</surname><given-names>K.</given-names></name><name><surname>Ohta</surname><given-names>J.</given-names></name><name><surname>Nakajima</surname><given-names>M.</given-names></name><name><surname>Kawashima</surname><given-names>T.</given-names></name><name><surname>Yoshikawa</surname><given-names>K.</given-names></name></person-group> (<year>1994</year>). <article-title>Alzheimer amyloid protein precursor enhances proliferation of neural stem cells from fetal rat brain</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>205</volume>, <fpage>936</fpage>–<lpage>943</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.1994.2755</pub-id><pub-id pub-id-type="pmid">7999135</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayward</surname><given-names>B. E.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Kumari</surname><given-names>D.</given-names></name><name><surname>Usdin</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>). <article-title>A set of assays for the comprehensive analysis of fMR1 alleles in the Fragile X-related disorders</article-title>. <source/>J. Mol. Diagn.
<volume>18</volume>, <fpage>762</fpage>–<lpage>774</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmoldx.2016.06.001</pub-id><pub-id pub-id-type="pmid">27528259</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>K. M.</given-names></name><name><surname>Gallagher</surname><given-names>S. M.</given-names></name><name><surname>Warren</surname><given-names>S. T.</given-names></name><name><surname>Bear</surname><given-names>M. F.</given-names></name></person-group> (<year>2002</year>). <article-title>Altered synaptic plasticity in a mouse model of fragile X mental retardation</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>99</volume>, <fpage>7746</fpage>–<lpage>7750</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.122205699</pub-id><pub-id pub-id-type="pmid">12032354</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalfallah</surname><given-names>O.</given-names></name><name><surname>Jarjat</surname><given-names>M.</given-names></name><name><surname>Davidovic</surname><given-names>L.</given-names></name><name><surname>Nottet</surname><given-names>N.</given-names></name><name><surname>Cestele</surname><given-names>S.</given-names></name><name><surname>Mantegazza</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Depletion of the fragile X mental retardation protein in embryonic stem cells alters the kinetics of neurogenesis</article-title>. <source/>Stem Cells
<volume>35</volume>, <fpage>374</fpage>–<lpage>385</lpage>. <pub-id pub-id-type="doi">10.1002/stem.2505</pub-id><pub-id pub-id-type="pmid">27664080</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>E. K.</given-names></name><name><surname>Kim</surname><given-names>H. H.</given-names></name><name><surname>Kuwano</surname><given-names>Y.</given-names></name><name><surname>Abdelmohsen</surname><given-names>K.</given-names></name><name><surname>Srikantan</surname><given-names>S.</given-names></name><name><surname>Subaran</surname><given-names>S. S.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>hnRNP C promotes APP translation by competing with FMRP for APP mRNA recruitment to P bodies</article-title>. <source/>Nat. Struct. Mol. Biol.
<volume>17</volume>, <fpage>732</fpage>–<lpage>739</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb.1815</pub-id><pub-id pub-id-type="pmid">20473314</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>L.</given-names></name><name><surname>Park</surname><given-names>S. K.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><name><surname>Vanderklish</surname><given-names>P.</given-names></name><name><surname>Yates</surname><given-names>J. R.</given-names><suffix>III</suffix></name></person-group> (<year>2008</year>). <article-title>Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>105</volume>, <fpage>15281</fpage>–<lpage>15286</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0804678105</pub-id><pub-id pub-id-type="pmid">18829439</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Shan</surname><given-names>G.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Smrt</surname><given-names>R. D.</given-names></name><name><surname>Johnson</surname><given-names>E. B.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Fragile X mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells</article-title>. <source/>PLoS Genet.
<volume>6</volume>:<fpage>e1000898</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1000898</pub-id><pub-id pub-id-type="pmid">20386739</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maloney</surname><given-names>B.</given-names></name><name><surname>Lahiri</surname><given-names>D. K.</given-names></name></person-group> (<year>2011</year>). <article-title>The Alzheimer's amyloid beta-peptide (Abeta) binds a specific DNA Abeta-interacting domain (AbetaID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: characterizing a new regulatory motif</article-title>. <source/>Gene
<volume>488</volume>, <fpage>1</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2011.06.004</pub-id><pub-id pub-id-type="pmid">21699964</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateu-Huertas</surname><given-names>E.</given-names></name><name><surname>Rodriguez-Revenga</surname><given-names>L.</given-names></name><name><surname>Alvarez-Mora</surname><given-names>M. I.</given-names></name><name><surname>Madrigal</surname><given-names>I.</given-names></name><name><surname>Willemsen</surname><given-names>R.</given-names></name><name><surname>Mila</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Blood expression profiles of fragile X premutation carriers identify candidate genes involved in neurodegenerative and infertility phenotypes</article-title>. <source/>Neurobiol. Dis.
<volume>65</volume>, <fpage>43</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2013.12.020</pub-id><pub-id pub-id-type="pmid">24418349</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolas</surname><given-names>M.</given-names></name><name><surname>Hassan</surname><given-names>B. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Amyloid precursor protein and neural development</article-title>. <source/>Development
<volume>141</volume>, <fpage>2543</fpage>–<lpage>2548</lpage>. <pub-id pub-id-type="doi">10.1242/dev.108712</pub-id><pub-id pub-id-type="pmid">24961795</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohsawa</surname><given-names>I.</given-names></name><name><surname>Takamura</surname><given-names>C.</given-names></name><name><surname>Morimoto</surname><given-names>T.</given-names></name><name><surname>Ishiguro</surname><given-names>M.</given-names></name><name><surname>Kohsaka</surname><given-names>S.</given-names></name></person-group> (<year>1999</year>). <article-title>Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cells</article-title>. <source/>Eur. J. Neurosci.
<volume>11</volume>, <fpage>1907</fpage>–<lpage>1913</lpage>. <pub-id pub-id-type="doi">10.1046/j.1460-9568.1999.00601.x</pub-id><pub-id pub-id-type="pmid">10336659</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasciuto</surname><given-names>E.</given-names></name><name><surname>Ahmed</surname><given-names>T.</given-names></name><name><surname>Wahle</surname><given-names>T.</given-names></name><name><surname>Gardoni</surname><given-names>F.</given-names></name><name><surname>D'Andrea</surname><given-names>L.</given-names></name><name><surname>Pacini</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Dysregulated ADAM10-mediated processing of APP during a critical time window leads to synaptic deficits in fragile X syndrome</article-title>. <source/>Neuron
<volume>87</volume>, <fpage>382</fpage>–<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2015.06.032</pub-id><pub-id pub-id-type="pmid">26182420</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaker</surname><given-names>J. M.</given-names></name><name><surname>Cargill</surname><given-names>R. S.</given-names></name><name><surname>Swanson</surname><given-names>T. L.</given-names></name><name><surname>Quirindongo</surname><given-names>H.</given-names></name><name><surname>Cassar</surname><given-names>M.</given-names></name><name><surname>Kretzschmar</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Amyloid precursor proteins are dynamically trafficked and processed during neuronal development</article-title>. <source/>Front. Mol. Neurosci.
<volume>9</volume>:<fpage>130</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2016.00130</pub-id><pub-id pub-id-type="pmid">27932950</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>B.</given-names></name><name><surname>Sokol</surname><given-names>D. K.</given-names></name><name><surname>Maloney</surname><given-names>B.</given-names></name><name><surname>Lahiri</surname><given-names>D. K.</given-names></name></person-group> (<year>2016</year>). <article-title>Finding novel distinctions between the sAPPalpha-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue</article-title>. <source/>Sci. Rep.
<volume>6</volume>:<fpage>26052</fpage>. <pub-id pub-id-type="doi">10.1038/srep26052</pub-id><pub-id pub-id-type="pmid">27212113</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renoux</surname><given-names>A. J.</given-names></name><name><surname>Carducci</surname><given-names>N. M.</given-names></name><name><surname>Ahmady</surname><given-names>A. A.</given-names></name><name><surname>Todd</surname><given-names>P. K.</given-names></name></person-group> (<year>2014</year>). <article-title>Fragile X mental retardation protein expression in Alzheimer's disease</article-title>. <source/>Front. Genet.
<volume>5</volume>:<fpage>360</fpage>. <pub-id pub-id-type="doi">10.3389/fgene.2014.00360</pub-id><pub-id pub-id-type="pmid">25452762</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>M. R.</given-names></name><name><surname>Bray</surname><given-names>S. M.</given-names></name><name><surname>Warren</surname><given-names>S. T.</given-names></name></person-group> (<year>2011</year>). <article-title>Molecular mechanisms of Fragile X syndrome: a twenty-year perspective</article-title>. <source/>Annu. Rev. Pathol. <volume>7</volume>, <fpage>219</fpage>–<lpage>245</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pathol-011811-132457</pub-id><pub-id pub-id-type="pmid">22017584</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokol</surname><given-names>D. K.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Farlow</surname><given-names>M. R.</given-names></name><name><surname>Dunn</surname><given-names>D. W.</given-names></name><name><surname>Maloney</surname><given-names>B.</given-names></name><name><surname>Zimmer</surname><given-names>J. A.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression</article-title>. <source/>J. Child Neurol.
<volume>21</volume>, <fpage>444</fpage>–<lpage>449</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pathol-011811-132457</pub-id><pub-id pub-id-type="pmid">16948926</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tassone</surname><given-names>F.</given-names></name></person-group> (<year>2014</year>). <article-title>Newborn screening for fragile X syndrome</article-title>. <source/>JAMA Neurol.
<volume>71</volume>, <fpage>355</fpage>–<lpage>359</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2013.4808</pub-id><pub-id pub-id-type="pmid">24395328</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tassone</surname><given-names>F.</given-names></name><name><surname>Greco</surname><given-names>C. M.</given-names></name><name><surname>Hunsaker</surname><given-names>M. R.</given-names></name><name><surname>Seritan</surname><given-names>A. L.</given-names></name><name><surname>Berman</surname><given-names>R. F.</given-names></name><name><surname>Gane</surname><given-names>L. W.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS</article-title>. <source/>Genes Brain Behav.
<volume>11</volume>, <fpage>577</fpage>–<lpage>585</lpage>. <pub-id pub-id-type="doi">10.1111/j.1601-183X.2012.00779.x</pub-id><pub-id pub-id-type="pmid">22463693</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>Y.</given-names></name><name><surname>Nakano</surname><given-names>S.</given-names></name><name><surname>Gomi</surname><given-names>F.</given-names></name><name><surname>Takahashi</surname><given-names>H.</given-names></name></person-group> (<year>2007</year>). <article-title>Differential regulation of basic helix-loop-helix factors Mash1 and Olig2 by beta-amyloid accelerates both differentiation and death of cultured neural stem/progenitor cells</article-title>. <source/>J. Biol. Chem.
<volume>282</volume>, <fpage>19700</fpage>–<lpage>19709</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M703099200</pub-id><pub-id pub-id-type="pmid">17488716</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Cole</surname><given-names>A. L.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>The amyloid precursor protein controls adult hippocampal neurogenesis through GABAergic interneurons</article-title>. <source/>J. Neurosci.
<volume>34</volume>, <fpage>13314</fpage>–<lpage>13325</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2848-14.2014</pub-id><pub-id pub-id-type="pmid">25274811</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Bolos</surname><given-names>M.</given-names></name><name><surname>Clark</surname><given-names>R.</given-names></name><name><surname>Cullen</surname><given-names>C. L.</given-names></name><name><surname>Southam</surname><given-names>K. A.</given-names></name><name><surname>Foa</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Amyloid beta precursor protein regulates neuron survival and maturation in the adult mouse brain</article-title>. <source/>Mol Cell Neurosci
<volume>77</volume>, <fpage>21</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.mcn.2016.09.002</pub-id><pub-id pub-id-type="pmid">27664851</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmark</surname><given-names>C. J.</given-names></name><name><surname>Berry-Kravis</surname><given-names>E. M.</given-names></name><name><surname>Ikonomidou</surname><given-names>C.</given-names></name><name><surname>Yin</surname><given-names>J. C.</given-names></name><name><surname>Puglielli</surname><given-names>L.</given-names></name></person-group> (<year>2013</year>). <article-title>Developing BACE-1 inhibitors for FXS</article-title>. <source/>Front Cell Neurosci
<volume>7</volume>:<fpage>77</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2013.00077</pub-id><pub-id pub-id-type="pmid">23754978</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmark</surname><given-names>C. J.</given-names></name><name><surname>Malter</surname><given-names>J. S.</given-names></name></person-group> (<year>2007</year>). <article-title>FMRP mediates mGluR5-dependent translation of amyloid precursor protein</article-title>. <source/>PLoS Biol
<volume>5</volume>:<fpage>e52</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pbio.0050052</pub-id><pub-id pub-id-type="pmid">17298186</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmark</surname><given-names>C. J.</given-names></name><name><surname>Sokol</surname><given-names>D. K.</given-names></name><name><surname>Maloney</surname><given-names>B.</given-names></name><name><surname>Lahiri</surname><given-names>D. K.</given-names></name></person-group> (<year>2016</year>). <article-title>Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism</article-title>. <source/>Mol Psychiatry
<volume>21</volume>, <fpage>1333</fpage>–<lpage>1341</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2016.134</pub-id><pub-id pub-id-type="pmid">27573877</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmark</surname><given-names>C. J.</given-names></name><name><surname>Westmark</surname><given-names>P. R.</given-names></name><name><surname>O'Riordan</surname><given-names>K. J.</given-names></name><name><surname>Ray</surname><given-names>B. C.</given-names></name><name><surname>Hervey</surname><given-names>C. M.</given-names></name><name><surname>Salamat</surname><given-names>M. S.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Reversal of Fragile X phenotypes by manipulation of AbPP/Ab levels in Fmr1 mice</article-title>. <source/>PLoS ONE
<volume>6</volume>:<fpage>e26549</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0026549</pub-id><pub-id pub-id-type="pmid">22046307</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>A. C.</given-names></name><name><surname>Sideris</surname><given-names>J.</given-names></name><name><surname>Hagerman</surname><given-names>R.</given-names></name><name><surname>Berry-Kravis</surname><given-names>E.</given-names></name><name><surname>Tassone</surname><given-names>F.</given-names></name><name><surname>Bailey</surname><given-names>D. B.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Developmental profiles of infants with an FMR1 premutation</article-title>. <source/>J. Neurodev. Disord.
<volume>8</volume>:<fpage>40</fpage>. <pub-id pub-id-type="doi">10.1186/s11689-016-9171-8</pub-id><pub-id pub-id-type="pmid">27822316</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>